Literature DB >> 30617940

Understanding the structural features of JAK2 inhibitors: a combined 3D-QSAR, DFT and molecular dynamics study.

Sathya Babu1, Santhosh Kumar Nagarajan1, Thirumurthy Madhavan2.   

Abstract

JAK2 plays a critical role in JAK/STAT signaling pathway and in patho-mechanism of myeloproliferative disorders and autoimmune diseases. Thus, effective JAK2 inhibitors provide a promising opportunity for the pharmaceutical intervention of many diseases. In this work, 3D-QSAR study was performed on a series of 1-amino-5H-pyrido-indole-4-carboxamide derivatives as JAK2 inhibitors to obtain reliable comparative molecular field analysis (CoMFA) and comparative molecular similarity analysis (CoMSIA) models with three different alignment methods. Among the different alignment methods, ligand-based (CoMFA: q2 = 0.676, r2 = 0.979; CoMSIA: q2 = 0.700, r2 = 0.953) and pharmacophore-based alignment (CoMFA: q2 = 0.710, r2 = 0.982; CoMSIA: q2 = 0.686, r2 = 0.960) has produced better statistical results when compared to receptor-based alignment (CoMFA: q2 = 0.507, r2 = 0.979; CoMSIA: q2 = 0.544, r2 = 0.917). Statistical parameters indicated that data are well fitted and have high predictive ability. The presence of electrostatic and hydrophobic field is highly desirable for potent inhibitory activity, and the steric field plays a minor role in modulating the activity. The contour analysis indicates ARG980, ASN981, ASP939 and LEU937 have more possibility of interacting with bulky, hydrophobic groups in pyrido and positive and negative groups in pyrazole ring. Based on our findings, we have designed sixteen molecules and predicted its activity and drug-like properties. Subsequently, molecular docking, molecular dynamics and DFT calculations were performed to evaluate its potency.

Entities:  

Keywords:  3D-QSAR; CoMFA; CoMSIA; DFT; JAK2; Molecular dynamics

Mesh:

Substances:

Year:  2019        PMID: 30617940     DOI: 10.1007/s11030-018-09913-4

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  56 in total

1.  Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors.

Authors:  Kh Dhanachandra Singh; Muthusamy Karthikeyan; Palani Kirubakaran; Selvaraman Nagamani
Journal:  J Mol Graph Model       Date:  2011-07-22       Impact factor: 2.518

2.  Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.

Authors:  Neal K Williams; Rebecca S Bamert; Onisha Patel; Christina Wang; Patricia M Walden; Andrew F Wilks; Emmanuelle Fantino; Jamie Rossjohn; Isabelle S Lucet
Journal:  J Mol Biol       Date:  2009-01-29       Impact factor: 5.469

3.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

Authors:  G Klebe; U Abraham; T Mietzner
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

4.  Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.

Authors:  Carole Pissot-Soldermann; Marc Gerspacher; Pascal Furet; Christoph Gaul; Philipp Holzer; Clive McCarthy; Thomas Radimerski; Catherine H Regnier; Fabienne Baffert; Peter Drueckes; Gisele A Tavares; Eric Vangrevelinghe; Francesca Blasco; Giorgio Ottaviani; Flavio Ossola; Julien Scesa; Janitha Reetz
Journal:  Bioorg Med Chem Lett       Date:  2010-02-19       Impact factor: 2.823

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 6.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

7.  Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors.

Authors:  Amy C Hart; Gretchen M Schroeder; Honghe Wan; James Grebinski; Jennifer Inghrim; James Kempson; Junqing Guo; William J Pitts; John S Tokarski; John S Sack; Javed A Khan; Jonathan Lippy; Matthew V Lorenzi; Dan You; Theresa McDevitt; Ragini Vuppugalla; Yueping Zhang; Louis J Lombardo; George L Trainor; Ashok V Purandare
Journal:  ACS Med Chem Lett       Date:  2015-07-10       Impact factor: 4.345

8.  Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).

Authors:  Christopher J Burns; David G Bourke; Laura Andrau; Xianyong Bu; Susan A Charman; Andrew C Donohue; Emmanuelle Fantino; Michelle Farrugia; John T Feutrill; Max Joffe; Marcel R Kling; Margarita Kurek; Tracy L Nero; Thao Nguyen; James T Palmer; Ian Phillips; David M Shackleford; Harrison Sikanyika; Michelle Styles; Stephen Su; Herbert Treutlein; Jun Zeng; Andrew F Wilks
Journal:  Bioorg Med Chem Lett       Date:  2009-08-23       Impact factor: 2.823

Review 9.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers.

Authors:  Shyh-Han Tan; Marja T Nevalainen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 10.  Alternative ways of modulating JAK-STAT pathway: Looking beyond phosphorylation.

Authors:  Olga A Timofeeva; Nadya I Tarasova
Journal:  JAKSTAT       Date:  2012-10-01
View more
  3 in total

1.  Structural modification of 4, 5-dihydro-[1, 2, 4] triazolo [4, 3-f] pteridine derivatives as BRD4 inhibitors using 2D/3D-QSAR and molecular docking analysis.

Authors:  Jian-Bo Tong; Ding Luo; Yi Feng; Shuai Bian; Xing Zhang; Tian-Hao Wang
Journal:  Mol Divers       Date:  2021-01-03       Impact factor: 2.943

2.  Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.

Authors:  A S Achutha; V L Pushpa; Surendran Suchitra
Journal:  J Proteome Res       Date:  2020-10-07       Impact factor: 4.466

3.  Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation.

Authors:  Chirag N Patel; Sivakumar Prasanth Kumar; Himanshu A Pandya; Rakesh M Rawal
Journal:  Mol Divers       Date:  2020-09-29       Impact factor: 2.943

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.